📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

📢How should we treat intermediate risk prostate cancer in older👴(and wiser!) men? In >22,000 men ≥60 years of age receiving dose-escalated RT, adding ADT had: ✅ OS benefit only in ages 60–69 ❌ No OS benefit in ≥ 70 📉ADT’s effectiveness decreases across decades, with the

@JackAndrewsMD highlighting our collaborative and exciting work on using tumor extracellular vesicles to risk stratify patients and predict response to SBRT in oligometastatic prostate cancer @MayoUrology @MayoRadOnc @aadel_chaudhuri @JakeOrmeMDPhD @piet_ost

Why this matters? MDT trials assume that treating visible mets influence outcomes. Our data suggest that baseline mets are the first to break through, MDT aims to interrupt this pattern This pattern provides biological rationale for ongoing MDT trials. e.g STAMPEDE 2

Our new study in @Nature @pcan_journal We report progression patterns in de novo oligo HSPC staged with PSMA-PET, treated with prostate but no MDT This allowed us to observe the natural history of PSMA defined oligometastatic disease. Fill paper link https://t.co/HGZ9jIUP0Q

My goal is to bridge science with the lived experience. And in the context of oligometastatic/progressive/persistent disease, the decision is more than the mutation, the number of sites, and the locations. This is my lung cancer experience condensed in one slide (timeline credit

7 days for a manuscript review with AI + human @NEJM_AI

I think AI-assisted review has potential to be far superior to current system. More objective, comprehensive, timely...particularly in 2025 when many decline to review for free (understandably) & volume of research papers is growing exponentially.

This zombie 🧟 idea that was never true and never alive and hence cannot die, is that cancer is fundamentally a druggable problem, that “Precision Medicine” and targeting one mutant gene is the solution. It’s not. Local therapies are key 🔑

Targeted Therapy is a mathematical self-fulfilling prophecy of failure We target one mutation hoping for a cure, but Luria-Delbrück proves the E[R]^th resistant seeds are already established and waiting

@jryckman3 Square pneumonia: https://t.co/7VUgLCBQTb

WPRT? Proton therapy? Both have been under fire lately in Prostate cancer. Instead of debating, we got data, and made a new start. This is the first peer-reviewed report of SBPT to prostate + whole pelvis using proton therapy. @ctRO_journal @ACTREC_TMC @ApolloProton

Please fell free to use this algorithm within your trials- and for your clinical practice 🙏 Full link to the code within the article!! 🤍 Thanks to the LTSI for their support and their trust for my PhD

🔐 One of the key limitation for the implementation of urinary organs-at-risk in treatment planning is the large interobserver variability 🔑 Here we provide a fully available nn-Unet method for automatic segmentation of these small urinary structures!

Excellent read: “Epic was never built to ingest or learn from this scale of data. It was built to satisfy billing requirements, regulatory checklists, and documentation workflows. That is the beginning and end of its architecture. It is not a learning system, much less an AI

|GnRH antagonists give faster LUTS relief in prostate cancer #PROSCA25 #GlobalForum25 Urinary symptoms matter in men starting RT plus ADT. Across multiple trials (Anderson, Mason, Axcrona), one signal is crystal clear: 🟦 Degarelix and other antagonists drop IPSS faster than

18F FDG PET CT in Bladder Cancer #GlobalForum25 #BLADDR25 PET CT is quietly becoming one of the most practice changing tools in MIBC. Why it matters: it picks up hidden mets that conventional staging often misses. 🧲 Diagnostic power Sensitivity around 89 percent, specificity

The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future

Conference travel costs add up & discretionary funds are limited. @SprakerMDPhD has generously committed to personally funding four $500 travel awards for trainees & patients. Application process minimal. Seems like a great opportunity.

The whole medical publishing ecosystem (free content, free peer review, but $$ to publish/read) is a bizarre, exploitative business model. Even if one believes clinicians owe some degree of unpaid "academic service," it’s absurd publishers profit so massively off our free labor.

🧨 Join us for #PCa #SBRT Symposium by @StAr_MCM74 & @PanizzaDenis with 🔝tier international faculty @piet_ost @CDraulans @CZamboglou and 🌟Italian RadOncs together with @ESTRO_RT President @BarbaraJereczek 🔗Registrations open—limited seats https://t.co/icoFJ27mw5 @valefacc22